Online inquiry

IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10088MR)

This product GTTS-WQ10088MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10088MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3211MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ1725MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ9584MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ12517MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ15536MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ9615MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ4243MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ6236MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CR57
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW